Donaldson Maria C, Katanayeva Natalya, Oricchio Elisa
Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Mol Cell Oncol. 2017 Sep 21;4(6):e1365107. doi: 10.1080/23723556.2017.1365107. eCollection 2017.
is a tumor suppressor in follicular lymphoma that controls mTORC1 activity and it is inactivated by chromosomal deletions or epigenetically silenced by mutant EZH2. Pharmacological inhibition of EZH2 promotes re-expression and it restores its tumor suppressive activity, suggesting the possibility to epigenetically control mTORC1 activity.
是滤泡性淋巴瘤中的一种肿瘤抑制因子,可控制mTORC1活性,它通过染色体缺失而失活,或因突变的EZH2而发生表观遗传沉默。对EZH2的药理学抑制促进其重新表达,并恢复其肿瘤抑制活性,这表明表观遗传控制mTORC1活性具有可能性。